Literature DB >> 7298848

Effect of cetiedil, an in vitro antisickling agent, on erythrocyte membrane cation permeability.

L R Berkowitz, E P Orringer.   

Abstract

Cetiedil has been reported to relieve painful crises in sickle cell anemia and to have antisickling properties in vitro. The drug alters neither oxygen affinity nor the solubility of deoxyhemoglobin S. Because the viscosity of the erythrocyte interior and the kinetics of gelation are dependent on the concentration of hemoglobin, we postulated that cetiedil might inhibit sickling by modifying erythrocyte sodium or potassium movements in a manner that would increase cell water content and thus dilute the cell hemoglobin. The drug has two such effects: it inhibits the specific increase in potassium permeability that follows a rise in cytoplasmic calcium concentration and it causes a rise in passive sodium movements. These effects are further evidence that cell ion and water movements may be important in the process of sickling and suggest a mechanism for the results reported with cetiedil.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7298848      PMCID: PMC370916          DOI: 10.1172/jci110367

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  19 in total

1.  The role of calcium in the potassium permeability of human erythrocytes.

Authors:  G GARDOS
Journal:  Acta Physiol Acad Sci Hung       Date:  1959

2.  Potassium and sodium of red blood cells in sickle cell anemia.

Authors:  D C TOSTESON; E SHEA; R C DARLING
Journal:  J Clin Invest       Date:  1952-04       Impact factor: 14.808

3.  Analysis of factors regulating erythrocyte deformability.

Authors:  N Mohandas; M R Clark; M S Jacobs; S B Shohet
Journal:  J Clin Invest       Date:  1980-09       Impact factor: 14.808

4.  Progressive inhibition of the Ca pump and Ca:Ca exchange in sickle red cells.

Authors:  R M Bookchin; V L Lew
Journal:  Nature       Date:  1980-04-10       Impact factor: 49.962

5.  Cetiedil: its potential usefulness in sickle cell disease.

Authors:  L J Benjamin; G Kokkini; C M Peterson
Journal:  Blood       Date:  1980-02       Impact factor: 22.113

6.  Deformability of oxygenated irreversibly sickled cells.

Authors:  M R Clark; N Mohandas; S B Shohet
Journal:  J Clin Invest       Date:  1980-01       Impact factor: 14.808

7.  Energy reserve and cation composition of irreversibly sickled cells in vivo.

Authors:  B E Glader; S E Lux; A Muller-Soyano; O S Platt; R D Propper; D G Nathan
Journal:  Br J Haematol       Date:  1978-12       Impact factor: 6.998

8.  Effect of cetiedil on erythrocyte sickling: new type of antisickling agent that may affect erythrocyte membranes.

Authors:  T Asakura; S T Ohnishi; K Adachi; M Ozguc; K Hashimoto; M Singer; M O Russell; E Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

9.  A study of induced hyponatremia in the prevention and treatment of sickle-cell crisis.

Authors:  R M Rosa; B E Bierer; R Thomas; J S Stoff; M Kruskall; S Robinson; H F Bunn; F H Epstein
Journal:  N Engl J Med       Date:  1980-11-13       Impact factor: 91.245

10.  Cation permeability alterations during sickling: relationship to cation composition and cellular hydration of irreversibly sickled cells.

Authors:  B E Glader; D G Nathan
Journal:  Blood       Date:  1978-05       Impact factor: 22.113

View more
  4 in total

1.  Oxpentifylline and cetiedil citrate improve deformability of dehydrated sickle cells.

Authors:  J Stuart; P C Stone; Y Y Bilto; A J Keidan
Journal:  J Clin Pathol       Date:  1987-10       Impact factor: 3.411

2.  Bepridil and cetiedil. Vasodilators which inhibit Ca2+-dependent calmodulin interactions with erythrocyte membranes.

Authors:  P Agre; D Virshup; V Bennett
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

3.  Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease.

Authors:  C Brugnara; B Gee; C C Armsby; S Kurth; M Sakamoto; N Rifai; S L Alper; O S Platt
Journal:  J Clin Invest       Date:  1996-03-01       Impact factor: 14.808

4.  Expression and Role of the Intermediate-Conductance Calcium-Activated Potassium Channel KCa3.1 in Glioblastoma.

Authors:  Luigi Catacuzzeno; Bernard Fioretti; Fabio Franciolini
Journal:  J Signal Transduct       Date:  2012-05-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.